Quantum BioPharma is trading at $3.25, up 5.17% after hours, with no clear catalyst identified.

  • The move compares with the October 6 regular-session close of $3.09; shares fell 5.50% during that session.
  • On October 6, Quantum BioPharma announced a Thermo Fisher agreement to support start-up of its Phase 2 Lucid-MS trial. Available coverage does not link the news to the after-hours rise.
  • Broader market context was positive, but does not establish a cause for the gain.